Company: STAA
Filing Date: 2025-10-30
Form Type: DEFA14A
Source: 0001193125-25-258558
Chunk: 19

Company: STAAR SURGICAL CO
Filing Date: 2025-10-30
Form: DEFA14A
Chunk 19
---
The following text is hereby added immediately before the last full paragraph of the section titled “Background of the Merger” on page 47 of the proxy statement:

The second full paragraph on page 40 of the proxy statement is hereby amended and supplemented as follows:

Thereafter, on February 26, 2025, Stephen Farrell, who had previously served as the lead independent
director of the Board, was appointed as the Chief Executive Officer of STAAR, and Elizabeth Yeu, M.D. was appointed to serve as Chair of the Board.Following Mr.Farrell’s appointment as Chief Executive Officer, Mr.Frinzi was not involved in any discussions regarding STAAR’s potential transaction with Alcon. On March 18, 2025, STAAR announced the appointment of
Deborah Andrews as its Interim Chief Financial Officer.

The following paragraph is added after the fourth full paragraph on page 40 of the proxy statement:

On April7, 2025, a representative of a privately-owned companyParty Cemailed Mr.Farrell and Dr.Yeu to express interest in exploring a potential business combination with STAAR. The outreach did not include any proposal on valuation, timing, diligence requirements, financing capability or other transaction terms.Party C subsequently confirmed to STAAR that “the outreach was an introductory email and was not intended as a proposal.” The email was not followed up on by Party C.

The last paragraph beginning on page 41 of the proxy statement is hereby amended and supplemented as follows:

On July 6, 2025, the
Board held a meeting to discuss a potential response to Alcon with members of STAAR’s management and representatives of Citi in attendance. Representatives of Citi reviewed their preliminary financial analysis of STAAR with the Board.
STAAR’s management discussed preliminary financial analyses it had conducted and indicated it would prepare multi-year financial projections for the Board’s consideration at a future meeting. Management noted that STAAR’s expense
profile was improved due to the reductions in operational costs, but that there remained uncertainty regarding the timing and durability of a recovery in refractive procedure volumes in China, which would impact revenue growth scenarios. In
addition, the Board considered additional risks and opportunities that could affect STAAR’s standalone business plan, including competitive threats, a potential trade war and related tariff risks, and the potential for price controls in China.
The Board then considered whether to solicit indications of interest from other third parties for a potential transaction with STAAR. Representatives of Citi reviewed the likely universe of potential